Skip to main content
SpringerLink
Log in

Menopausale Hormonersatztherapie und gynäkologische Tumorerkrankungen

Menopausal hormone replacement therapy and gynecological tumorous diseases

  • Leitthema
  • Published:
Gynäkologische Endokrinologie Aims and scope

Zusammenfassung

Die Hormonersatztherapie in der Menopause ist eine der meist rezeptierten medikamentösen Behandlungen der Frau. Die Therapie führt in den meisten Fällen zu einer deutlichen Linderung der klimakterischen Beschwerden und somit zu einer Steigerung der Lebensqualität. Die Indikation zur Therapie sollte jedoch nur streng im Sinne der Leitlinienempfehlungen gestellt werden. Die Entstehung der 3 häufigsten gynäkologischen Tumorerkrankungen wird durch eine Hormonersatztherapie in Abhängigkeit von Präparat, Applikationsart und Dauer in unterschiedlicher Weise beeinflusst. Vor Beginn der Hormontherapie sollte daher eine differenzierte Aufklärung der Patientin unter Abwägung des individuellen Risikos erfolgen, sodass die mündige Patientin in die Therapieentscheidung miteinbezogen werden kann.

Abstract

Hormone replacement therapy is one of the most regularly prescribed medications among menopausal women. Estrogen or combined estrogen-gestagen therapy leads to a significant reduction of climacteric symptoms and therefore improves the quality of life. There are clear guidelines concerning indications for hormone substitution which have to be followed. The three most common gynecological cancer types are influenced (according to specific substance, type of application and durance of intake) in different ways. Before starting hormone therapy, the medical specialist is beholden to precisely inform the patient about individual risk factors and expected benefits so that the patient can make an objective decision.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Anderson GL, Judd HL, Kaunitz AM et al (2003) Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: The Women’s Health Initiative randomized trial. JAMA 290:1739–1748

    Article  PubMed  CAS  Google Scholar 

  2. Ayhan A, Taskiran C, Simsek S, Sever A (2006) Does immediate hormone replacement therapy affect the oncologic outcome in endometrial cancer survivors? Int J Gynecol Cancer 16:805–808

    Article  PubMed  CAS  Google Scholar 

  3. Beral V, Million Women Study Collaborators, Bull D et al (2007) Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 369:1703–1710

    Article  PubMed  CAS  Google Scholar 

  4. Brinton LA, Richesson D, Leitzmann MF et al (2008) Menopausal hormone therapy and breast cancer risk in the NIH-AARP diet and health study cohort. Cancer Epidemiol Biomarkers Prev 17:3150–3160

    Article  PubMed  CAS  Google Scholar 

  5. De Geyter CH (2009) Menopausale Hormontherapie. Nutzen und Risiken. Ars Medici Schweizer Zeitschrift für Hausarztmedizin 4:144–148

    Google Scholar 

  6. Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (2009) Hormontherapie in der Peri- und Postmenopause. Interdisziplinäre S3-Leitlinie

  7. Emons G (2001) Hormonsubstitution und Endometriumkarzinom. Journal für Menopause

  8. Grady D, Gebretsadik T, Kerlikowske K et al (1995) Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 85:304–313

    Article  PubMed  CAS  Google Scholar 

  9. Horwitz KB, Sartorius CA (2008) Progestins in hormone replacement therapies reactivate cancer stem cells in women with preexisting breast cancers: a hypothesis. J Clin Endocrinol Metab 93:3295–3298

    Article  PubMed  CAS  Google Scholar 

  10. Hsia J, Langer RD, Manson JE et al (2006) Conjugated equine estrogens and coronary heart disease: the Women’s Health Initiative. Arch Intern Med 166:357–365

    Article  PubMed  CAS  Google Scholar 

  11. LeBlanc ES, Janowsky J, Chan BK, Nelson HD (2001) Hormone replacement therapy and cognition: systematic review and meta-analysis. JAMA 285:1489–1499

    Article  PubMed  CAS  Google Scholar 

  12. Li CI, Malone KE, Porter PL et al (2008) Relationship between menopausal hormone therapy and risk of ductal, lobular, and ductal-lobular breast carcinomas. Cancer Epidemiol Biomarkers Prev 17:43–50

    Article  PubMed  Google Scholar 

  13. Mascarenhas C, Lambe M, Bellocco R et al (2006) Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival. Int J Cancer 119:2907–2915

    Article  PubMed  CAS  Google Scholar 

  14. Morch LS, Lokkegaard E, Andreasen AH et al (2009) Hormone therapy and ovarian cancer. JAMA 302:298–305

    Article  PubMed  Google Scholar 

  15. Nelson HD, Haney E, Humphrey L et al (2005) Management of menopause-related symptoms. Evid Rep Technol Assess (Summ) 120:1–6

    Google Scholar 

  16. Perrotta C, Aznar M, Mejia R et al (2008) Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. Obstet Gynecol 112:689–690

    Article  PubMed  CAS  Google Scholar 

  17. Prentice RL, Chlebowski RT, Stefanick ML et al (2008) Conjugated equine estrogens and breast cancer risk in the Women’s Health Initiative clinical trial and observational study. Am J Epidemiol 167:1407–1415

    Article  PubMed  Google Scholar 

  18. Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333

    Article  PubMed  CAS  Google Scholar 

  19. Sismondi P, Biglia N (2004) HRT and gynaecologic cancer after WHI: old stuff or new doubts? Maturitas 48:13–18

    Article  PubMed  CAS  Google Scholar 

  20. Welton AJ, Vickers MR, Kim J et al (2008) Health related quality of life after combined hormone replacement therapy: Randomised controlled trial. BMJ 337:a1190

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Gynäkologie und Geburtshilfe, Universitätsklinikum Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Deutschland

    M. Wolf & L. Kiesel

Authors
  1. M. Wolf
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. Kiesel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Wolf.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wolf, M., Kiesel, L. Menopausale Hormonersatztherapie und gynäkologische Tumorerkrankungen. Gynäkologische Endokrinologie 9, 161–164 (2011). https://doi.org/10.1007/s10304-011-0415-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10304-011-0415-0

Schlüsselwörter

Keywords

Search

Navigation